AI assistant
Celldex Therapeutics, Inc. — Director's Dealing 2021
Jan 4, 2021
31801_dirs_2021-01-04_9f6b13ca-250b-42b1-a38f-a04905d9575d.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 3 — Initial Statement of Beneficial Ownership
Issuer: Celldex Therapeutics, Inc. (CLDX)
CIK: 0000744218
Period of Report: 2021-01-01
Reporting Person: Jimenez Freddy A. (SVP & General Counsel)
Holdings (Derivative)
| Security | Exercise Price | Expiration | Underlying | Shares | Ownership |
|---|---|---|---|---|---|
| Employee Stock Option (right to buy) | $112.50 | 2026-03-01 | Common Stock (1400) | Direct | |
| Employee Stock Option (right to buy) | $70.80 | 2026-06-08 | Common Stock (733) | Direct | |
| Employee Stock Option (right to buy) | $65.40 | 2026-08-11 | Common Stock (266) | Direct | |
| Employee Stock Option (right to buy) | $34.80 | 2027-06-15 | Common Stock (1666) | Direct | |
| Employee Stock Option (right to buy) | $9.0165 | 2028-06-13 | Common Stock (4166) | Direct | |
| Employee Stock Option (right to buy) | $2.78 | 2029-06-19 | Common Stock (20000) | Direct | |
| Employee Stock Option (right to buy) | $10.38 | 2030-06-18 | Common Stock (36000) | Direct |
Footnotes
F1: The option became exercisable as to 25% of the shares on March 1, 2017 and the remaining shares vested quarterly (in equal amounts) over the subsequent 12 quarters. This option is currently fully vested.
F2: The option became exercisable as to 25% of the shares on June 8, 2017 and the remaining shares vested quarterly (in equal amounts) over the subsequent 12 quarters. This option is currently fully vested
F3: The option became exercisable as to 25% of the shares on August 11, 2017 and the remaining shares vested quarterly (in equal amounts) over the subsequent 12 quarters. This option is currently fully vested.
F4: The option became exercisable as to 25% of the shares on June 15, 2018 and the remaining shares vest quarterly (in equal amounts) over the subsequent 12 quarters.
F5: The option became exercisable as to 25% of the shares on June 13, 2019 and the remaining shares vest quarterly (in equal amounts) over the subsequent 12 quarters.
F6: The option became exercisable as to 25% of the shares on June 19, 2020 and the remaining shares vest quarterly (in equal amounts) over the subsequent 12 quarters.
F7: The option becomes exercisable as to 25% of the shares on June 18, 2021 and the remaining shares vest quarterly (in equal amounts) over the subsequent 12 quarters.